

Confirmed Speakers

Confirmed Speakers

Ehrlich Prize Winner

Natural Antitumor Macrolides Acting on Tubulin: Synthesis and Functional Exploration



Prof. Karl-Heinz ALTMANN
(SCS DMCCB & SWISS FEDERAL INSTITUTE OF TECHNOLOGY, Zürich, Switzerland)

PDE10A Inhibitors as Potential Treatments for Schizophrenia



Dr Jose Manuel BARTOLOME
(JANSSEN RESEARCH & DEVELOPMENT, Toledo, Spain)

Recent Advances in Predicting Cardiac Risk during Drug Development



Dr Arthur BROWN
(CHANTEST, Cleveland, United States)

Excursions in Uncharted Structural Space



Prof. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

Novel Imidazoles as Selective TAAR1 Partial Agonists for the Treatment of Psychiatric Disorders



Dr Giuseppe CECERE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Exploiting the Information Rich Output of SPR Biosensor Technology in Drug Discovery – From Target Evaluation to Fragment and Lead



Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

Translational Biophysics: Using Biophysical Data in Medicinal Chemistry



Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Use of Peptides to Modulate Protein-Protein Interactions



Prof. Ernest GIRALT
(INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB), Barcelona, Spain)

Discovery and Optimisation of a Novel Series of EZH2 Inhibitors, Challenges and Clinical Perspectives

Confirmed Speakers



Dr Jean-Christophe HARMANGE
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Molecular Basis of Ligand Dissociation from GPCRs – a Molecular Dynamics and Mutagenesis Study on the Adenosine A_{2A} Receptor



Prof. Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

The Design and Optimisation of Selective Protein Kinase C Theta Inhibitors for the Treatment of Autoimmune Diseases



Dr Juan-Miguel JIMENEZ
(VERTEX PHARMACEUTICALS, Abingdon, United Kingdom)

Cell Identity Loss in Cancer: a Source of New Biomarkers and Therapeutic Targets



Dr Saadi KHOCHBIN
(JOSEPH FOURIER UNIVERSITY, Grenoble, France)

The Lab Oddity Prevails - Discovery of pan-CDK Inhibitor BAY 1000394 (Roniciclib) for the Treatment of Cancer



Dr Ulrich LÜCKING
(BAYER HEALTHCARE, Basel, Switzerland)

Targeting BAX for Cancer Therapy: from Computer Screen to Mouse



Dr Luciana MARINELLI
(UNIVERSITY OF NAPOLI, Napoli, Italy)

Polar Units and Dipolar Interactions Modulating, Conformation, Lipophilicity, and other Physicochemical Properties



Prof. Klaus MÜLLER
(F. HOFFMANN-LA ROCHE, Switzerland)

Specific Antidotes for Dabigatran: Structure-Guided Affinity Optimisation and Functional Characterisation



Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

High-Throughput Chemical Microarray SPR: The Biophysical Tool for Fragment Based Screening in Drug Discovery

Confirmed Speakers



Dr Thomas NEUMANN
(GRAFFINITY PHARMACEUTICALS, Illkirch, France)

Discovery of TAK-632: Pan-RAF Inhibitor with Potent Antitumor Activity against *BRAF* and *NRAS* Mutant Melanomas



Dr Masanori OKANIWA
(TAKEDA PHARMACEUTICAL COMPANY, Kanagawa, Japan)

Chemical Probes for Epigenetics



Dr Dafydd OWEN
(PFIZER, Cambridge, United States)

Design and Applications of Protein Epitope Mimetics



Prof. John ROBINSON
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

Pseudo-Natural Product Synthesis and Drug Applications



Prof. Hiroaki SUGA
(UNIVERSITY OF TOKYO, Tokyo, Japan)

2-Clips Peptides: A Novel Class of Biopharmaceuticals



Prof. Peter TIMMERMAN
(PEPSCAN THERAPEUTICS, Lelystad, The Netherlands)

Genotoxicity Screening can guide Lead Optimisation and Reduce Late Stage Attrition



Prof. Richard WALMSLEY
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

Strategies to Target Protein-Protein Interactions: from Discovery to Clinical Development



Prof. Shaomeng WANG
(UNIVERSITY OF MICHIGAN, Michigan, United States)

Short Communications

Identification of Cell-penetrating Compounds and their Use for Intracellular Delivery of Cathepsin D Inhibitors

Confirmed Speakers



Prof. Muriel AMBLARD
(CNRS-UNIVERSITY OF MONTPELLIER I, Montpellier, France)

Silicon-containing Tetrahydrocyclopenta[c]acridine Derivatives as CDKs Inhibitors: Design, Organometallic Synthesis, Metabolic Stability and Optimisation



Prof. Philippe BELMONT
(UNIVERSITY PARIS DESCARTES, Paris, France)

Innovative Fluorescent-Based Approaches to GPCR Screening and Functional Architecture Studies



Prof. Dominique BONNET
(UNIVERSITY OF STRASBOURG, Illkirch, France)

Combining Organic Synthesis, Software Development and Biochemistry for the Design and Discovery of Prolyl oligopeptidase Inhibitors



Prof. Nicolas MOITESSIER
(MCGILL UNIVERSITY, Montreal, Canada)